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Background: We sought to determine whether circulating inflammatory biomarkers were 
associated with the frequent exacerbator phenotype in stable COPD patients ie, those with 
two or more exacerbations in the previous year.
Methods: Eighty-eight stable, severe, COPD patients (4 females) were assessed for exacer-
bation frequency, pulmonary function, fraction of expired nitric oxide (FENO); inflammatory 
variables were measured in venous blood. Logistic regression assessed associations between 
the frequent exacerbator phenotype and systemic inflammation.
Results: Compared with infrequent exacerbators, frequent exacerbators (n=10; 11.4%) had 
greater serum concentration (median (25th-75th quartile)) of serum amyloid A (SAA; 134 
(84–178) vs 71 (38–116) ng/mL; P=0.024), surfactant protein D (SP-D; 15.6 (9.0–19.3) vs 
8.5 (3.6–14.9) ng/mL; P=0.049) and interleukin-4 (IL-4; 0.12 (0.08–1.44) vs 0.03 (0.01–-
0.10) pg/mL; P=0.001). SAA, SP-D and IL-4 were not significantly correlated with FEV1% 
predicted or FVC %predicted. After adjusting for sex, age, BMI, FEV1/FVC and smoking 
pack-years, only SAA remained independently associated with the frequent exacerbator 
phenotype (OR 1.49[1.09–2.04]; P=0.012). The odds of being a frequent exacerbator was 18- 
times greater in the highest SAA quartile (≥124.1 ng/mL) than the lowest SAA quartile 
(≤44.1 ng/mL) (OR 18.34[1.30–258.81]; P=0.031), and there was a significant positive trend 
of increasing OR with increasing SAA quartile (P=0.008). For SAA, the area under the 
receiver operating characteristic curve was 0.721 for identification of frequent exacerbators; 
an SAA cut-off of 87.0 ng/mL yielded an 80% sensitivity and 61.5% specificity.
Conclusion: In stable COPD patients, SAA was independently associated with the frequent 
exacerbator phenotype, suggesting that SAA may be a useful serum biomarker to inform 
progression or management in COPD.
Keywords: inflammation, surfactant protein D, interleukin-4
Background
Chronic obstructive pulmonary disease (COPD) is characterized by both an accelerated 
decline in lung function and periods of acute deterioration in symptoms, termed 
exacerbations. Exacerbations of respiratory symptoms in COPD are of major impor-
tance in terms of their prolonged detrimental effects on patients.1 Frequent exacerba-
tions contribute to long-term decline in lung function as well as to increased morbidity, 
decreased quality of life, and increased mortality of patients with moderate to severe 
COPD.2–4 Some patients experience frequent exacerbations, and form a distinct clinical 
subgroup, the ‘frequent exacerbator’ phenotype, in contrast to patients who experience 
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few exacerbations over time.5 The frequent exacerbator phe-
notype is recognized as a major phenotype in patients with 
COPD and occurs across disease severities.5
Exacerbations are typically caused by respiratory tract 
infections.6 During an acute exacerbation episode, the existing 
airway and systemic inflammation increase further.7–9 
Inflammatory mediators, cytokines and chemokines are 
released into the circulation and induce recruitment of inflam-
matory cells into the lung parenchyma. Besides local damage 
to lung structures, activation of immune cells causes systemic 
inflammation with increases in acute phase proteins such as 
fibrinogen and C-reactive protein (CRP).7,10 The airways of 
frequent exacerbators are more inflamed than those with infre-
quent exacerbations, and frequent exacerbators have greater 
concentration of sputum interleukin-6 (IL-6) and −8 (IL-8).11 
In addition, during the exacerbation recovery period, sputum 
IL-6 and serum CRP are greater in the frequent exacerbator 
phenotype,12 consistent with their greater baseline inflamma-
tory state. In the post-exacerbation recovery period, greater 
serum concentration of inflammatory mediators, such as CRP, 
are associated with a shorter time until the next exacerbation.12 
As a result, CRP has been proposed as a predictive biomarker 
for COPD exacerbation.13
Similar to CRP, serum amyloid A (SAA) is an acute phase 
inflammatory biomarker, and is strongly associated with 
COPD exacerbations.14 Bozinovski et al14 studied stable and 
exacerbating COPD patients, and found that SAA was four- 
fold greater in patients experiencing a severe acute COPD 
exacerbation. They also identified that the increase in SAA 
was a more sensitive indicator of acute COPD exacerbation 
than CRP alone or in combination with dyspnea.14
SAA is a family of proteins that form a major compo-
nent of the acute-phase inflammatory response and, like 
CRP, is synthesized mainly in the liver in response to 
infection, inflammation, injury, or stress.15 Considering 
that SAA is a sensitive marker of an acute inflammatory 
state, we aimed to determine the association between the 
frequent exacerbator phenotype of COPD and SAA con-
centration in the stable state of COPD. We hypothesized 
that greater SAA is associated with the frequent exacer-
bator phenotype in COPD and that the relationship is 
stronger than for other markers of inflammation.
Methods
Patient Population
This cross-sectional study was conducted at the First 
Affiliated Hospital of Guangzhou Medical University. 
Patients with severe to very severe COPD (GOLD 
[Global Initiative for Chronic Obstructive Lung Disease] 
spirometry stages 3–4),16 were recruited during their stable 
state. Exclusion criteria included a COPD exacerbation 
within the previous 4 weeks, lung cancer, bronchiectasis, 
pneumoconiosis or other restrictive ventilatory dysfunc-
tion and chronic systemic inflammatory conditions. 
Information collected included medical and smoking his-
tory, exacerbation frequency, pulmonary function and frac-
tion of expired nitric oxide (FENO). Venous blood was 
collected and serum was assessed for inflammatory vari-
ables. The study protocol was approved by the Medical 
Ethics Review Committee of the First Affiliated Hospital 
of Guangzhou Medical University and all subjects pro-
vided written informed consent. The study was conducted 
in accordance with the principles of the Declaration of 
Helsinki, except for prospective public trial registration.
Subgroups
Moderate and severe exacerbations were captured by 
a review of medical records. Moderate exacerbations 
were defined as an acute worsening of respiratory symp-
toms treated by antibiotics and/or oral steroids and severe 
exacerbations as a worsening of respiratory symptoms 
requiring hospitalization or emergency room visit.16 
Frequent exacerbations were defined as two or more 
exacerbations in the previous year.16,17 Subjects were 
divided into two groups: 1) “frequent exacerbators”, who 
experienced two or more moderate or severe exacerbations 
in the 12 months prior to study enrollment; 2) “infrequent 
exacerbators”, who had one or no exacerbations in the 12 
months prior to study enrollment.
Blood Sampling and Measurement of 
Inflammatory Markers
Venous blood samples were collected from subjects by 
venipuncture in plain tubes. The samples were centrifuged 
immediately at 2500 rpm for 15 minutes at room tempera-
ture and the serum fraction was collected and frozen at −80° 
C pending subsequent procedures. The concentration of 
SAA (R&D, #DY3019-05), SP-D (R&D, #DSFPD0), 
PRG4 (SAB, #EK2481), LTB4 (Abcam, #ab133040), 
MMP-8 (R&D, #DMP800), MMP-9 (Bioscience, #85- 
BMS2016-2) were measured in the serum by an enzyme- 
linked immunosorbent assay (ELISA). The concentration of 
GM-CSF, IL-1β, IL-4, IL-6 and IL-8 were measured using 
human cytokine V-PLEX validated immunoassay kit (Meso 
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Scale Discovery, Gaithersburg, MD). Blood cell counts 
were made using a hematological analyzer (DxH 800, 
Beckman Coulter, California, United States). All the mea-
surements were performed in duplicate. The average of 
each variable is reported.
Pulmonary Function Testing
Spirometry was performed by using a portable spirometer 
(Carefusion MasterScreen Pneumo, Germany) before, and 
20 minutes after, inhalation of 400μg of short-acting β2- 
agonist (albuterol) in accordance with the ERS/ATS 
recommendations.18 Spirometric data were reviewed and 
graded by a quality control software (Sentrysuite V.2.3). 
Predicted values were calculated according to the use of 
the reference values from the European Coal and Steel 
Community (1993) and the application of conversion fac-
tors for Chinese adults (male: 0.95, female: 0.93).19
Fractional Exhaled Nitric Oxide (FENO)
FENO was measured by using the NIOX system 
(NioxMino® ENO analyzer, Aerocrine, Sweden) in accor-
dance with ATS/ERS recommendations.20 FENO was mea-
sured before spirometry and measured three times, with 
differences ≤10% indicating acceptable variance. The 
mean value of three measurements is reported.
Statistical Analysis
Data were expressed as mean ± standard deviation (SD) or 
median (25th-75th quartiles) or as percentage. Univariate 
analyses included independent-samples Student’s t or 
Mann–Whitney test for continuous variables or chi- 
square test or Fisher’s exact test for categorical variables 
between two groups, as appropriate. SAA concentration 
was divided in quartiles. Relationships among frequent 
exacerbator phenotype (dependent variable) and clinical 
data, spirometric values, inflammatory variables and SAA 
(square root (sqrt) transformed) (independent variables) 
were assessed by logistic regression. A multivariable 
logistic regression model was adjusted for age, sex, smok-
ing pack-years, body mass index and FEV1/FVC. The 
trend for linearity between the odds ratio (OR) and SAA 
quartiles was estimated by logistic regression including 
the median of each SAA quartile as a continuous variable. 
The optimal SAA cut-off point (highest sum of sensitivity 
and specificity) to identify frequent exacerbators was 
selected using receiver operating characteristic (ROC) 
analysis. Correlations between inflammatory variables 
and pulmonary function were assessed by Spearman 
correlation. All statistical analyses were performed using 
SPSS (IBM SPSS V.25.0, Armonk, NY, USA). Statistical 
significance was set at P<0.05. Figures were created using 
GraphPad Software (GraphPad Prism V.8.0 for Windows, 
San Diego, California USA).
Results
Patient Characteristics
A total of 88 patients were enrolled. Patient characteristics 
are shown in Table 1. Overall, the group was predominantly 
male (96%), aged 64±7 years with severe or very severe 
COPD (FEV1 38±9%predicted). Ten (11.4%) patients were 
frequent exacerbators (3 (2–4) exacerbations in the previous 
12 months), while 78 (88.6%) were infrequent exacerbators 
(0 (0–1) exacerbations in the previous 12 months). Frequent 
exacerbators had a significantly greater CAT score (13 
(9–16) vs 9 (6–12); P=0.028), greater mMRC dyspnea 
scale (2 (1–3) vs 1 (1–2); P=0.001), a lower post- 
bronchodilator (BD) FVC (2.01±0.40 vs 2.66±0.60 L; 
P=0.001), and lower post-BD FVC %predicted (58.3±10.9 
vs 75.9±15.8%predicted; P=0.001). There was no significant 
difference between the two groups in age, sex, BMI, current 
smoker status, smoking pack-years, post-BD FEV1, post-BD 
FEV1%predicted or post-BD FEV1/FVC. There was no sig-
nificant difference between the two groups in total white cell 
count, or count or percentage of neutrophils and eosinophils 
(Table 1).
Inflammatory Variables in Groups Based 
on Exacerbation Frequency
SAA was significantly greater in frequent exacerbators 
compared to infrequent exacerbators (P=0.024) (Table 2; 
Figure 1A). Similarly, SP-D (P=0.049; Figure 1B) and IL- 
4 (P=0.001; Figure 1C) concentrations were significantly 
greater in frequent exacerbators compared to infrequent 
exacerbators (Table 2). There was no significant difference 
between the two groups in other inflammatory variables 
including IL-1β, IL-6, IL-8, CRP, LTB4, GM-CSF, FENO, 
MMP8, MMP9 and PRG4 (Table 2).
Correlations Between SAA, SP-D, IL-4 
and Pulmonary Function
Table 3 shows Spearman correlation between SAA, SP-D, 
IL-4 and spirometric measures of pulmonary function. For 
these three inflammatory markers, there was no significant 
correlation with post-BD FVC %predicted, post-BD FEV1 
%predicted, and post-BD FEV1/FVC (Table 3).
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Association Between SAA and Frequent 
Exacerbations
In the univariate logistic regression models, SAA was 
significantly associated with frequent exacerbator status 
(OR 1.33; 95% CI 1.03–1.70; P=0.027). SP-D, IL-4 and 
other inflammatory variables including IL-1β, IL-6, IL-8, 
CRP, LTB4, GM-CSF, FENO, MMP8, MMP9, PRG4 were 
not significantly associated with frequent exacerbator sta-
tus (Figure 2A). In the multivariable logistic regression 
model, adjusting for sex, age, BMI, Post-BD FEV1/FVC 
Table 1 Patient Characteristics
Variable Total (n=88) Infrequent Exacerbators (n=78) Frequent Exacerbators (n=10) P value
Age, year 64.2±7.3 63.9±7.4 66.5±6.3 0.288
Male, n (%) 84 (96%) 75 (96%) 9 (90%) 0.388
BMI, kg/m2 21.5±3.7 21.5±3.7 21.4±3.5 0.970
Post-BD FVC, L 2.59±0.62 2.66±0.60 2.01±0.40 0.001
Post-BD FVC %predicted 73.9±16.3 75.9±15.8 58.3±10.9 0.001
Post-BD FEV1, L 1.03±0.29 1.05±0.19 0.90±0.25 0.124
Post-BD FEV1%predicted 37.8±9.4 38.2±9.1 34.3±11.5 0.211
Post-BD FEV1/FVC 40.6±9.2 39.9±8.8 45.5±11.2 0.070
Exacerbations/year, n 0 (0–1) 0 (0–1) 3 (2–4) <0.001
Current smoker, n (%) 30 (34%) 27 (36%) 3 (30%) 0.359
Smoking pack-years 34.7±24.3 34.0±24.6 40.2±22.3 0.451
CAT score 9 (6–12) 9 (6–12) 13 (9–16) 0.028
mMRC dyspnea scale 1 (1–2) 1 (1–2) 2 (1–3) 0.001
White cell count,109/L 6.93 (6.03–8.29) 6.93 (6.02–8.34) 6.72 (6.02–8.04) 0.602
Neutrophil count, 109/L 4.20 (3.35–5.55) 4.20 (3.35–5.60) 4.10 (3.25–5.15) 0.559
Neutrophils, (%) 62.5±10.6 62.4±10.6 62.9±11.3 0.899
Eosinophil count, 109/L 0.24 (0.12–0.38) 0.25 (0.13–0.43) 0.11 (0.09–0.26) 0.089
Eosinophils, (%) 3.3 (1.9–5.5) 3.5 (2.2–5.9) 1.7 (1.2–4.3) 0.137
Notes: Data mean±SD or median (25th–75th interquartile range) or percentage. Infrequent exacerbators are defined as patients with 1 or fewer exacerbations in the 
previous year. Frequent exacerbators are defined as patients with 2 or more exacerbations in the previous year. 
Abbreviations: BMI, body mass index; BD, bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV1%pred, percentage of predicted 
FEV1; FVC%pred, percentage of predicted FVC; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnea scale.
Table 2 Inflammatory Variables in Groups Based on Exacerbation Frequency
Variables Infrequent Exacerbators (n=78) Frequent Exacerbators (n=10) P value
SAA (ng/mL) 71 (38–116) 134 (84–178) 0.024
SP-D (ng/mL) 8.46 (3.64–14.91) 15.57 (9.00–19.27) 0.049
IL-1β (pg/mL) 0.09 (0.01–0.19) 0.05 (0.01–0.26) 0.496
IL-4 (pg/mL) 0.03 (0.01–0.10) 0.12 (0.08–1.44) 0.001
IL-6 (pg/mL) 0.70 (0.32–1.07) 0.60 (0.42–2.61) 0.854
IL-8 (pg/mL) 5.09 (4.22–6.53) 4.90 (3.85–6.30) 0.617
CRP (mg/dl) 0.21 (0.08–0.74) 0.20 (0.12–0.90) 0.533
LTB4 (ng/mL) 278 (166–354) 279 (162–333) 0.737
GM-CSF (pg/mL) 0.04 (0.01–0.14) 0.01 (0.00–0.13) 0.788
FENO (ppb) 22.0 (16.3–31.0) 18.0 (14.5–27.5) 0.457
MMP8 (pg/mL) 681 (446–1136) 679 (457–2014) 0.604
MMP9 (ng/mL) 123 (81–182) 134 (74–156) 0.905
PRG4 (ng/mL) 54.2±22.2 40.5±23.1 0.101
Notes: Data median (25th–75th interquartile range) or mean±SD. Infrequent exacerbators are defined as patients with 1 or fewer exacerbations in the previous year. 
Frequent exacerbators are defined as patients with 2 or more exacerbations in the previous year. 
Abbreviations: SAA, serum amyloid A; SP-D, surfactant protein D; IL-1β, interleukin-1β; IL-4, interleukin-4; IL-6, interleukin-6; IL-8, interleukin-8; CRP, C-reactive protein; 
LTB4, leukotriene B4; GM-CSF, granulocyte-macrophage colony-stimulating factor; FENO, fractional exhaled nitric oxide; MMP-8, matrix metalloproteinase-8; MMP-9, matrix 
metalloproteinase-9; PRG4, proteoglycan 4.
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and smoking pack-years, SAA was independently asso-
ciated with the frequent exacerbator phenotype (OR 1.49; 
95% CI 1.09–2.04; P=0.012) (Figure 2B).
Associations Between SAA Quartiles and 
Frequent Exacerbations
The odds ratio for the association of frequent exacerbator 
status with quartiles of SAA concentration is presented in 
Figure 3. After adjusting for sex, age, BMI, Post-BD FEV1 
/FVC and smoking pack-years, the hazard of frequent exacer-
bator status in the highest SAA quartile (≥124.1 ng/mL) was 
18 times that of the lowest SAA quartile (≤44.1 ng/mL) (OR 
18.34; 95% CI 1.30–258.81; P=0.031). In categorical analy-
sis, we found that a significant linear association between the 
OR for frequent exacerbator status and increasing SAA 
quartile (P value for trend=0.008) (Figure 3).
Sensitivity and Specificity of SAA to 
Identify the Frequent Exacerbator 
Phenotype
In ROC analysis, yielded an area under the curve (AUC) 
of 0.721 (95% CI 0.542–0.899) for the identification of 
frequent exacerbators. The greatest sum of sensitivity and 
specificity (1.421) was an SAA of 131.7 ng/mL, 
corresponding to a sensitivity of 60.0% and specificity of 
82.1% (Figure 4). However, choosing to increase test 
sensitivity (at least 80.0%) did not meaningfully reduce 
the sum (1.415) and resulted in an SAA of 87.0 ng/mL 
corresponding to a sensitivity of 80.0% and specificity 
of 61.5%.
Discussion
The principal finding of this study was that the serum 
concentrations of SAA, SP-D and IL-4 were greater in 
COPD patients who experienced 2 or more exacerbations 
in the preceding year compared with those who did not. In 
addition, SAA, but not the other inflammatory biomarkers, 
was significantly associated with the frequent exacerbator 
phenotype after adjusting for potential covariates and was 
independent of spirometric measures of pulmonary impair-
ment and total eosinophil counts or percentage. We also 
found that the risk of frequent exacerbator status in the 
highest SAA quartile was 18 times of those in the lowest 
quartile, suggesting that SAA might be a good indicator of 
the frequent exacerbator phenotype in COPD. ROC ana-
lysis identified SAA = 87.0 ng/mL as providing 80% 
sensitivity to separate infrequent from frequent exacerba-
tors. Although the inflammatory biomarker SAA is known 
Figure 1 Comparison of SAA, SP-D and IL-4 concentration between frequent exacerbators and infrequent exacerbators. Frequent exacerbators (n=10) are defined as 
patients with 2 or more exacerbations in the previous year. Infrequent exacerbators (n=78) are defined as patients with 1 or none exacerbations in the previous year. (A) 
SAA concentration. (B) SP-D concentration. (C) IL-4 concentration. Statistical comparisons by Mann–Whitney test.
Table 3 The Correlation Between SAA, SP-D, IL-4 and Pulmonary Function
Variables Post-BD FEV1%pred Post-BD FVC%pred Post-BD FEV1/FVC
R Value P value R Value P value R Value P value
SAA −0.113 0.148 −0.145 0.090 0.023 0.416
SP-D 0.016 0.881 −0.033 0.759 0.074 0.495
IL-4 −0.077 0.503 −0.069 0.547 0.045 0.697
Abbreviations: BD, bronchodilator; FEV1%pred, percentage of predicted FEV1; FVC%pred, percentage of predicted FVC; SAA, serum amyloid A; SP-D, surfactant protein 
D; IL-4, interleukin-4.
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to be raised during an acute COPD exacerbation,14 this is 
the first study to our knowledge to demonstrate an associa-
tion of SAA with the frequent exacerbator phenotype in 
stable phase of COPD. This observational study cohort 
contained ~10% frequent exacerbators, which is reflective 
of the incidence expected in clinical practice. Further 
research is needed to validate these findings in an inde-
pendent cohort. Nevertheless, these data show that SAA 
may be a useful and sensitive biomarker to identify 
patients at risk of frequent exacerbations, to inform pro-
gression and to guide management of COPD.
Investigators have long sought a circulating biomarker 
that separates non-exacerbators from exacerbators. In the 
ECLIPSE trial, 2138 COPD patients were followed for 
three years to determine predictors of exacerbations. 
None of the measured circulating biomarkers were inde-
pendent predictors of exacerbation frequency. More 
recently, Gulati and colleagues reported a greater concen-
tration of fibroblast growth factor 23 (FGF23) in frequent 
exacerbators compared with patients without frequent 
exacerbations.21 In addition, these investigators showed 
that FGF23 is independently associated with frequent 
exacerbations, after adjusting for age, lung function, smok-
ing and oxygen use.21
Previous studies showed that SAA is dramatically 
increased during acute phase of a COPD exacerbation, 
and that SAA is a sensitive biomarker for exacerbation 
severity in COPD patients.14 Other studies showed 
increased circulating SAA concentration in COPD and 
other pulmonary diseases such as idiopathic pulmonary 
fibrosis (IPF).22–24 Formiga et al reported that inspiratory 
muscle performance was considerably lower in COPD 
patients with greater SAA concentration.23 In addition, 
SAA was greater in patients with IPF than in healthy 
controls.22 Furthermore, serum levels of SAA and CRP 
together with other inflammatory markers (eg, IL-6, IL-8, 
TNF-a, IP-10) were significantly greater in COPD patients 
experiencing an exacerbation than during remission and in 
healthy control subjects.24
Elevated SAA was reported in patients with cardiovascu-
lar disease where COPD was a comorbidity.25 Since half of 
the deaths in COPD are associated with cardiovascular 
events, and the incidence of these events increases dramati-
cally after each exacerbation,26,27 and also because SAA is 
a good predictor of coronary artery disease as well as future 
cardiovascular events, SAA might be considered as 
a potential indicator of frequent exacerbation phenotype as 
well as an indicator of comorbid cardiovascular disease.
As well as acting as a biomarker for the frequent 
exacerbator phenotype during the stable phase of COPD, 
evidence suggests that SAA may mediate an acute COPD 
exacerbation.14 SAA induces lung inflammation in COPD 
by promoting lung neutrophilia, which is activated by 
increasing expression of IL-17a in γδT cells.28 In addition, 
Figure 2 Odds ratio for variables associated with the frequent exacerbator phenotype. (A) Univariate logistic regression models. (B) Multivariable logistic regression model 
adjusting for sex, age, BMI, FEV1/FVC and smoking pack-years. SAA was square root (sqrt) transformed to normalize its distribution.
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SAA activates the NLRP3 inflammasome and elicits 
robust TLR2-, MyD88-, and IL-1-dependent pulmonary 
inflammation.29 Consistent with this, SAA is found in the 
lungs and bronchoalveolar lavage fluid of smoke exposed 
COPD patients and endotoxin-challenged mice.30,31
In stable COPD patients, we also showed that the 
circulating concentration of SP-D was greater in frequent 
exacerbators compared to infrequent exacerbators, 
although SP-D was not independently associated with 
exacerbation. Although no previous study compared the 
serum concentration of SP-D between frequent and infre-
quent exacerbators, the ECLIPSE study showed that SP- 
D significantly, although weakly, predicted exacerbation 
during the first year of follow-up.17 SP-D is mainly 
produced by type II alveolar cells in the lung,32 and is 
involved in regulating pulmonary surfactants, lipid home-
ostasis and innate immunity in order to protect the lungs 
from pathogens.33–35 SP-D has many protective proper-
ties including anti-inflammatory and anti-oxidant 
functions34 that associate with protection against the 
development of COPD.36 SP-D knockout mice have 
large lungs with enlarged airspaces and activated macro-
phages; they develop progressive pulmonary emphysema 
and subpleural fibrosis in association with chronic 
inflammation.37 In this study, we did not have chest-CT 
or diffusing capacity measures to identify whether the 
greater SP-D in frequent exacerbators was associated 
with greater pulmonary emphysema, although this might 
be expected.
A major role of SP-D is to regulate antibody-independent 
immune responses against invading microorganisms.38 
Indeed, SP-D deficient mice are more susceptible to respira-
tory infections with Pneumocystis carinii, influenza, respira-
tory syncytial virus, and bacteria.39–42 This is consistent with 
the observation that COPD patients with serum SP-D 
Figure 3 Associations between SAA quartiles and the frequent exacerbator phenotype. Multivariable logistic regression model adjusting for sex, age, BMI, FEV1/FVC and 
smoking pack-years. SAA concentration was divided in quartiles: Q1, ≤44.1 ng/mL; Q2, 44.2–76.7 ng/mL; Q3, 76.8–124.0 ng/mL; Q4, ≤124.1 ng/mL. Linear association 
between OR and SAA quartile was assessed by P for trend using logistic regression model including the median of each SAA quartile as a continuous variable.
Figure 4 Receiver operating characteristic (ROC) for identification of the frequent 
exacerbator phenotype by serum amyloid A (SAA). ROC analysis yielded an area 
under the curve (AUC) of 0.721 (95% CI 0.542–0.899) for the identification of 
frequent exacerbators. The greatest sum of sensitivity and specificity occurred at 
SAA = 131.7 ng/mL. Selection of a higher specificity (at least 80%) did not mean-
ingfully reduce the sum and resulted in SAA = 87.0 ng/mL to separate frequent and 
infrequent exacerbators, corresponding to a sensitivity of 80.0% and specificity of 
61.5%.
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concentration greater than the 95th percentile of nonsmokers 
had an increased risk of exacerbation over the following 12 
months.43
Our results showed no significant correlation between 
serum SP-D and spirometric lung function (FEV1%pred, 
FVC%pred, FEV1/FVC), which is consistent with several 
other studies.43 The interpretation of association of serum 
SP-D and lung function is complicated in that serum SP-D 
is affected not only by lung synthesis, but also by 
increased leakage of SP-D from the COPD lung into the 
systemic circulation.36 Nevertheless, in our study, SP-D 
was not as strongly (or independently) associated with the 
frequent exacerbator phenotype as SAA.
We also found serum IL-4 was significantly greater in 
frequent exacerbators, but regression analysis showed no 
significant independent correlation between IL-4 and 
exacerbator phenotype in our stable COPD patients. IL-4 
is secreted by Th-2 lymphocytes which stimulate the pro-
liferation of B lymphocytes to produce IgG and IgE, and 
to mediate humoral immunization.44 To our knowledge, 
this is the first study showing greater concentration of IL-4 
in frequent than infrequent exacerbators. Previous studies 
showed that serum IL-4 is greater in COPD patients during 
an acute exacerbation compared with stable COPD and 
control groups.45 Additionally, IL-4 concentration was 
dramatically increased in Mycoplasma pneumoniae- 
induced airway diseases, including those occurring in 
COPD patients.46 These data suggest that Th2 secreted 
cytokines (eg, IL-4) might play an important role in redu-
cing inflammation. Based on this rationale, greater IL-4 in 
frequent exacerbators compared with infrequent exacerba-
tors might indicate a protective role of Th2 lymphocytes 
and their secreted cytokines in balancing immune system 
function during acute infection and exacerbation. On the 
other hand, increased concentration of IL-4 due to hyper- 
activated Th2 cells might increase the concentration of IgE 
immunoglobulin which leads to airway hyper- 
responsiveness in exacerbating COPD patients.45 In this 
regard, the greater IL-4 in frequent exacerbators could 
reflect increased eosinophilic inflammation, although we 
found no difference in eosinophilia between frequent and 
infrequent exacerbators. We also did not find a correlation 
between IL-4 concentration and spirometric pulmonary 
function.
This study has limitations. We enrolled fewer frequent 
exacerbators than infrequent exacerbators. This might affect 
our ability to detect differences between the two groups. In 
addition, our study suffers from gender imbalance. The 
majority of our subjects were men (96%), limiting our ability 
to assert whether our findings also apply to women with 
COPD. This observational study was not large enough to 
provide separate discovery and validation sub-groups. 
Nevertheless, that we were able to identify the utility of 
SAA to identify the frequent exacerbator phenotype with 
a small sample size, suggests that these findings are worth 
exploring in a larger cohort to validate our findings. In order to 
increase the clinical utility of SAA to identify frequent exacer-
bators, we chose to prioritize sensitivity over specificity in 
identifying an SAA cut-off. Nevertheless, this choice resulted 
in summed sensitivity and specificity (1.415) that was not 
meaningfully different from the maximum value (1.421), 
where specificity was 80%.
Conclusions
This study demonstrated that serum SAA, SP-D and IL-4 
concentration were greater in stable COPD patients who 
had 2 or more exacerbations in the previous year com-
pared with those who experienced 1 or none. Further, SAA 
was significantly and independently correlated with the 
frequent exacerbator phenotype but not with spirometric 
indices of lung function. SAA should be considered as 
a potential biomarker of the frequent exacerbator pheno-
type in COPD. These findings provide new insights into 
the phenotyping COPD and may be useful to inform 
management of COPD patients.
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